Date published: 2026-1-26

1-800-457-3801

SCBT Portrait Logo
Seach Input

HRPAP20 Activators

The category of HRPAP20 activators mainly consists of indirect modulators, as there are no well-established direct chemical activators for HRPAP20. These compounds influence various signaling pathways and post-translational modifications that are related to the functional context of HRPAP20, a member of the Ras-related protein family. The indirect modulation approach for influencing HRPAP20 activity involves targeting the post-translational modification processes like farnesylation and geranylgeranylation, which are crucial for the proper functioning of many Ras-related proteins. Farnesyltransferase inhibitors (FTIs) and Geranylgeranyltransferase inhibitors (GGTIs) are key agents in this aspect. They hinder the attachment of lipid groups to these proteins, which is essential for their proper localization and function within the cell. Additionally, statins, known for their cholesterol-lowering effects, also play a role in modulating these post-translational modifications, as they inhibit HMG-CoA reductase, a key enzyme in the mevalonate pathway that provides precursors for lipid modifications.

Furthermore, the signaling pathways associated with Ras-related proteins, such as the MAPK/ERK and PI3K/Akt pathways, offer another avenue for indirectly modulating HRPAP20 activity. Compounds like MEK inhibitors (PD98059, U0126, Trametinib) and PI3K inhibitors (LY294002, Wortmannin) impact these pathways, which are downstream of Ras-related protein activity. This indirect modulation can influence the overall signaling dynamics in which HRPAP20 is involved. In summary, the strategy for modulating HRPAP20 activity largely relies on influencing the broader signaling networks and post-translational modification processes associated with Ras-related proteins. This approach reflects the complex nature of cellular signaling and the interconnectivity of various pathways and molecular modifications in determining the functional outcomes of proteins like HRPAP20. Understanding these indirect interactions is crucial for grasping the nuances of targeting specific components within the dense network of cellular signaling.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin inhibits mTOR, a kinase that is part of signaling pathways involving Ras-related proteins, possibly impacting HRPAP20.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is a specific inhibitor of PI3K, potentially affecting HRPAP20 activity indirectly via the PI3K/Akt pathway.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059 is a MEK inhibitor, potentially modulating HRPAP20 activity through the MAPK/ERK pathway.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin is a potent PI3K inhibitor, potentially affecting HRPAP20 activity through alterations in the PI3K/Akt pathway.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib targets multiple kinases and may indirectly affect HRPAP20 through its broad-spectrum kinase inhibition.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

Trametinib is a MEK inhibitor, potentially modulating HRPAP20 activity in the MAPK/ERK signaling pathway.